Drs. Karl and Spencer talk to Dr. Kenneth Qiu all about direct medical care - the future of medicine.Learn about how bypassing insurance and creating a relationship directly with a doctor can improve your health and save money in the long run.Follow Dr. Qiu on Linked inSee Dr. Spencer's direct care model with Vineyard

In this engaging conversation, Dr. Grant Tinsley, an Associate Professor at Texas Tech University and a body composition expert, discusses the impact of tirzepatide, a leading weight loss medication, on muscle loss. He clarifies the differences between fat-free mass, lean mass, and muscle, emphasizing the importance of precise language in the field. Tinsley also examines how DEXA scans can motivate weight training, strategies to preserve muscle while using tirzepatide, and the need for a holistic approach to muscle growth through nutrition and exercise.

Drs. Karl and Spencer discuss how bad the Hims and Hers ad was.From an outside perspective, the ad may have seemed good.But when you dig deeper, it was actually really bad.Listen to learn.Join Dr. Spencer's new online clinic - Vineyard.

Dr. Charles Brenner, an expert on NAD metabolism and longevity supplements, joins the conversation to break down the science behind NAD and NMN. He explains how NAD coenzymes are crucial for energy metabolism and discusses their decline with age. The chat dives into the misconceptions surrounding these supplements and critiques popular longevity claims made by figures like Andrew Huberman and Peter Atiyah. Brenner emphasizes the importance of a healthy lifestyle over reliance on unproven treatments, making it clear that foundational health practices are essential.

Drs. Karl and Spencer chat with Dr. Fatima Cody Stanford all about obesity, genetics, and her appearance on 60 minutes.Does Dr. Sanford believe lifestyle doesn't matter for obesity?Find out by listening!Watch Dr. Stanford's 60 minute clip Join Dr. Spencer's Obesity Clinic

Drs. Karl and Spencer chat about the new Lancet Commission's report on Clinical Obesity along with the new study on high dosed Wegovy. Learn:How 7.2 mg of Wegovy (semaglutide) compares to 2.4 mgWhat the proposed definitions of clinical and preclinical obesity areClick here to join Dr. Spencer's new online clinic

This week, Alexandra Sowa, author of "The Ozempic Revolution," joins to discuss groundbreaking GLP-1 medications and their impact on weight management. She sheds light on why she wrote her book and shares crucial tips for those considering these treatments. The conversation also tackles the societal stigmas associated with obesity, revealing the psychological hurdles patients face. With laughter and insightful dialogue, they explore the evolution of obesity medicine and the importance of education in combating misinformation.

Delve into the intriguing concepts of microdosing GLP-1 receptor agonists and the latest results from a new weight loss drug. Discover the balance between ethical medication access and corporate practices in healthcare. Hear about the eccentric quest for longevity and the disparities in medication availability. Explore the implications of microdosing terzepatide on inflammation versus weight loss. Unpack the ethical concerns surrounding cosmetic weight loss medications and the importance of responsible pharmaceutical practices.

Dr. Lauren Colenso-Semple, a PhD researcher specializing in exercise and menstrual cycles, shares her expertise on how menstrual phases should influence workout plans. She discusses the impact of hormone fluctuations on resistance training and the need for customized approaches as women experience their cycles differently. Myths surrounding hormonal contraceptives are debunked, while the significance of strength training for women is emphasized. Dr. Colenso-Semple advocates for more tailored fitness regimens that consider these unique physiological changes.

The podcast dives into the results of the Surmount 5 trial, comparing Zepbound and Wegovy for weight loss. The discussion highlights the benefits of these medications, including cardiovascular effects and safety profiles. A fascinating study on GLP-1 medications revealing reduced alcohol consumption adds an intriguing angle. The risks of misusing compounded GLP-1s are also examined, drawing attention to patient safety and regulatory issues. Finally, there’s a lighthearted critique of societal attitudes towards obesity treatment and the role of big pharma.